Cancel

Novel Breast Cancer Therapies: Antibody-Drug Conjugates

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s...
i3 Health

Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit...
i3 Health

Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma

STATEMENT OF NEED Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis...
i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ...
i3 Health

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

STATEMENT OF NEED Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f...
i3 Health

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ...
i3 Health

Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting

In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care. Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i...
Penn State College of Medicine

Improving Outcomes for Adolescent/Young Adult and Adult Patients with ALL: Evaluating the Impact of Immunotherapy

Target Audience The activity is intended primarily for hematology/oncology and medical oncology physicians and advanced practitioners caring for adult and AYA patients. Pediatric hematology/oncology and oncology clinicians who care for AYA patients may also find this material useful. Program Overview On-demand Oncology Expert Exchange: Clinical Case Challenge activity (Virtual Video Roundtable with Clinical Cases) with compelling reinforcing features. This initiative aims to close knowled...
Catalyst Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare

Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i...
Relias LLC

Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship

Target Audience The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists. Program Overview New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the...
Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD)

Clinical ShowCase™ in aHUS: The Application of Complement Inhibitors in Practice

Target Audience This educational activity is directed toward hematologists, nephrologists, primary care physicians, physician assistants, nurse practitioners, and nurses specializing in hematology and transplant medicine who may encounter patients with atypical hemolytic uremic syndrome (aHUS). Program Overview This online activity is designed to provide concise and easy-to-digest education in an engaging and interactive case-based format. The case focuses on diagnosing aHUS and choosing ...
Physicians’ Education Resource®, LLC

Transfusion-Related Iron Overload"Evidence-Based Approaches to Improve Chelation Outcomes

Target Audience This educational activity is directed toward hematologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with iron overload are also invited to attend. Program Overview Patients who require ongoing red blood cell transfusions, such as individuals with transfusion-dependent thalassemia or sickle cell disease, may develop iron overload. Severe or long-term iron overload can result in a higher ri...
Physicians’ Education Resource®, LLC.

Nursing Management of Cancer Treatment-Induced Cardiotoxicity

Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity. STATEMENT OF NEED Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in som...
i3 Health

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

ACTIVITY DESCRIPTION Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Community Practice Connections™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease

Target Audience This educational activity is directed toward hematologists, nurses, and other health care professionals involved in the treatment of patients with CKD-related anemia. Program Overview Anemia is a common complication in chronic kidney disease (CKD) and is associated with a reduced quality of life, an increase in morbidity and mortality and higher costs. Anemia is associated with major complications for patients with CKD, including impaired cognition, sleep disturbance, and ...
Physicians’ Education Resource®, LLC

Community Practice Connections™: Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan

Target Audience This activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other HCPs involved in the management of patients with SCD. Program Overview Significant progress has been made in the management of sickle cell disease (SCD) in recent years, leading to increased life expectancy for patients. The number of available medications continues to grow; further, novel agents and gene therapies on...
Physicians’ Education Resource®, LLC.

Community Practice Connections™: Exploring the Potential Role for Gene Therapy in Hemophilia B

Target Audience This activity is directed toward hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia B are invited to participate. Activity Overview In hemophilia B, an absence of clotting factor IX leads to a failure to facilitate and stabilize the primary platelet and fibrin plug that initially forms a clot. As a result, patients experience prolonged blee...
Physicians’ Education Resource®, LLC.

A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL

Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f...
The University of Texas MD Anderson Cancer Center

Ace the Case: Multiple Myeloma Presentation in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC

Target Audience Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC Program Overview Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on tar...
Relias LLC

Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?

Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
American Academy of CME

Ace the Case: Older Adult with Therapy-Related AML

Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
American Academy of CME

Ace the Case: Supporting Older Adults with AML

Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
American Academy of CME

Expert Illustrations & Commentaries™: Targeting the Complement System to Optimize Treatment of Cold Agglutinin Disease

Target Audience This educational activity is directed toward hematologists. Nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with cold agglutinin disease are invited to attend. Activity Overview This Expert Illustrations and Commentaries™ is a video-based program in which 2 experts discuss strategies for the management of cold agglutinin disease (CAD). In this activity, the faculty focus on the role of the complement system i...
Relias LLC

Evolving Treatments and Management Considerations for Patients with Hemophilia A

Target Audience This educational activity is directed toward hematologists and specialty nurse practitioners and physician assistants involved in the management of patients with hemophilia A. Activity Overview This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on current and emerging therapies for patients with hemophilia A. The engaging, multimedia format of this program includes audio commentary from an expe...
Relias LLC

On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma

Program Overview On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma. Target Audience The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and ot...
Relias LLC

Gene Therapy for Hemophilia B"The Next Step Forward in Disease Management

Target Audience This educational activity is directed toward hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia B are invited to attend. Activity Overview Gene therapy for hemophilia B has the potential to reduce the treatment burden for patients and their care partners by eliminating the need for regular prophylaxis through long-term expression of endogen...
Relias LLC

Real-World Perspectives in Managing CLL Treatment

Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ...
Purdue University College of Pharmacy

Warm Autoimmune Hemolytic Anemia (wAIHA)

Target Audience This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate. Program Overview Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis. Current recommendations for managing ...
American Academy of CME, Inc. and and CheckRare CE.

Diagnosis and Management of Patients With Predominant Skin Symptoms

The educational design of this activity addresses the needs of allergy/clinical immunology, gastroenterology, dermatology, and hematology clinicians who manage patients with nonadvanced systemic mastocytosis. Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and ...
Integritas Communications

How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r...
ACHL

Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ...
Postgraduate Institute for Medicine and RME Collaborative.

Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a...
Talem Health and RME Collaborative.

Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ...
Postgraduate Institute for Medicine and RME Collaborative.

Making the Call in Nonadvanced Systemic Mastocytosis Optimizing Multidisciplinary Management

Series Overview Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the...
Integritas Communications

Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.
Annenberg Center for Health Sciences at Eisenhower

Expanding the Benefit of Quality Improvement Programs: Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

Achieve measurable changes to improve your patients’ outcomes with this simple, systematic approach for quality improvement for application at any practice setting. Complete an assessment to understand where your practice’s performance falls relative to identified goals, which guides development of personalized action items. Access the framework and tools you need to measure your understanding.
ACHL

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ...
ACHL

Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

When it comes to treating your patients with myelofibrosis (MF), are you applying the latest guidance in practice? Evidence shows that it takes an average of 17 years for evidence to change practice but how can we incorporate treatment advances to improve patient outcomes today? This activity looks to bridge the chasm between education and implementation by framing available evidence and guideline recommendations for MF, including diagnosis, risk stratification, JAK inhibition, monitoring resp...
ACHL

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map